Helical peptidomimetic compounds as inhibitors of beta-amyloid production
are provided. These inhibitors have sequences with lengths from 11 to 16
amino acids, inclusive. These inhibitors potently inhibit intramembrane
proteases, notably aspartyl secretases involved in the enzymatic cleavage
of amyloid precursor protein (APP) to yield amyloid-.beta.-peptide.
Methods are provided for making a medicament containing the compounds and
for administering the compounds to treat .beta.-amyloid-associated
diseases, notably Alzheimer's disease.